XML 58 R25.htm IDEA: XBRL DOCUMENT
v3.20.4

Equity | 12 Months Ended
--- | ---
Dec. 31, 2020
Notes to Consolidated Financial Statements [Abstract] |
Note 19 - Equity | Note 19 – Equity A. Composition:
| As at December 31, 2020 | As at December 31, 2019
| Authorized | Issued and paid | Authorized | Issued and paid
Number of Ordinary shares of Israeli Shekel 1 par value (in millions) | 1,485 | * 1,305 | 1,485 | * 1,305
Number of Special State share of Israeli Shekel 1 par value | 1 | 1 | 1 | 1
(*) For information regarding the amount of treasury shares, see Note 19.G.(1). The reconciliation of the number of shares outstanding at the beginning and at the end of the year is as follows:
| Number of Outstanding Shares (in millions)
As at January 1, 2019 | 1,305
Issuance of shares | -
As at December 31, 2019 | 1,305
Issuance of shares | -
As at December 31, 2020 | 1,305
B. Rights conferred by the shares The ordinary shares grant their holders voting rights in General Meetings of the Company, the right to participate in shareholders’ meetings, the right to receive dividends and the right to a share in excess assets upon liquidation of ICL. The Special State of Israel Share, held by the State of Israel in order to monitor matters of vital interest to the State of Israel, grants special rights to make decisions, among other things, on the following matters: Sale or transfer of Company assets, which are “essential” to the State of Israel, not in the ordinary course of business. Voluntary liquidation, change or reorganization of the organizational structure of ICL or merger (excluding mergers of entities controlled by ICL, directly or indirectly, that would not impair the rights or power of the Government, as holder of the Special State Share). Any acquisition or holding of 14% or more of the issued share capital of ICL. The acquisition or holding of 25% or more of the issued share capital of ICL (including augmentation of an existing holding up to 25%), even if there was previously an understanding regarding a holding of less than 25%. Note 19 – Equity (Cont'd) B. Rights conferred by the shares (cont'd) Any percentage of holding of the Company’s shares, which grants its holder the right, ability or actual possibility to appoint, directly or indirectly, such number of the Company’s directors equal to half or more of the Company’s directors appointed. During the second half of 2018, an inter-ministry team was established, headed by the Ministry of Finance, whose purpose is, among other things, to regulate the authority and supervision in respect of the Special State of Israel Share, as well as reduce the regulatory burden. In 2019, the work of this team was suspended until further notice due to the dissolution of the Knesset and lack of permanent Government. The Company is unable to estimate when or whether the team will recommence and what are the implications of this process over the Company, if any. Note 19 – Equity (cont'd) C. Share-based payments Non-marketable options
Grant date | Employees entitled | Number of instruments (thousands) | Issuance's details | Instrument terms | Vesting conditions | Expiration date
August 6, 2014 | Officers and senior employees | 3,993 | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan. | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case that on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap. | 3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018 | Two years from the vesting date.
December 11, 2014 | Former CEO | 367
May 12, 2015 | Officers and senior employees | 6,729 | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
June 29, 2015 | Former CEO | 530
Former chairman of BOD | 404
June 30, 2016 | Officers and senior employees | 3,035 | June 30, 2023
September 5, 2016 | Former chairman of BOD | 186
February 14, 2017 | Former CEO | 114 | February 14, 2024
June 20, 2017 | Officers and senior employees | 6,868 | June 20, 2024
August 2, 2017 | Former chairman of BOD | 165
Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Non-marketable options (cont'd)
Grant date | Employees entitled | Number of instruments (thousands) | Issuance's details | Instrument terms | Vesting conditions | Expiration date
March 6, 2018 | Officers and senior employees | 5,554 | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan. | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | March 6, 2025
May 14, 2018 | CEO | 385 | May 14, 2025
August 20, 2018 | Former chairman of BOD | 403 | August 20, 2025
April 15, 2019 | Officers and senior manager | 13,242 | 2 equal tranches: (1) half at the end of 24 months after the grant date. (2) half at the end of 36 months after the grant date. | 5 years after the grant date
June 27, 2019 | CEO | 3,512
May 29, 2019 * | Chairman of BOD | 2,169 | 2 equal tranches: (1) half at the end of 24 months after the issuance date. (2) half at the end of 36 months after the issuance date. | 5 years after the issuance date
* The options were issued upon Mr. Doppelt's entry into office on July 1, 2019. Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Non-marketable options (cont'd) Additional Information The options issued to the employees in Israel are covered by the provisions of Section 102 of the Israeli Income Tax Ordinance. The issuance is performed through a trustee under the Capital Gains Track. The exercise price is linked to the CPI that is known as of the date of payment, which is the exercise date. In a case of distribution of a dividend by the Company, the exercise price is reduced on the “ex dividend” date, by the amount of the dividend per share (gross), based on the amount thereof in NIS on the effective date. The fair value of the options granted in 2014, as part of 2014 equity compensation plan, as amended, was estimated using the binomial model for pricing options. The grants in 2015, 2016, 2017, 2018 and 2019 under the 2014 Equity Compensation Plan, as amended, were estimated using the Black & Scholes model for pricing options. The parameters used in applying the models are as follows:
| 2014 Plan
| Granted 2014 | Granted 2015 | Granted 2016 | Granted 2017 | Granted 2018 | Granted 2019 |
Share price (in $) | 8.2 | 7.0 | 3.9 | 4.5 | 4.4 | 5.4
CPI-linked exercise price (in $) | 8.4 | 7.2 | 4.3 | 4.3 | 4.3 | 5.3
Expected volatility: |  |  |  |  |  |
First tranche | 29.40% | 25.40% | 30.51% | 31.88% | 28.86% | 27.85%
Second tranche | 31.20% | 25.40% | 30.51% | 31.88% | 28.86% | 27.85%
Third tranche | 40.80% | 28.80% | 30.51% | 31.88% | 28.86% | 27.85%
Expected life of options (in years): |  |  |  |  |  |
First tranche | 4.3 | 3.0 | 7.0 | 7.0 | 7.0 | 4.4
Second tranche | 5.3 | 3.0 | 7.0 | 7.0 | 7.0 | 4.4
Third tranche | 6.3 | 4.0 | 7.0 | 7.0 | 7.0 | 4.4
Risk-free interest rate: |  |  |  |  |  |
First tranche | (0.17)% | (1.00)% | 0.01% | 0.37% | 0.03% | (0.67)%
Second tranche | 0.05% | (1.00)% | 0.01% | 0.37% | 0.03% | (0.67)%
Third tranche | 0.24% | (0.88)% | 0.01% | 0.37% | 0.03% | (0.67)%
Fair value (in $ millions) | 8.4 | 9.0 | 4.0 | 11.3 | 8.8 | 7.5
Weighted average grant date fair value per option (in $) | 1.9 | 1.2 | 1.1 | 1.6 | 1.4 | 1.2
Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Non-marketable options (cont'd) The expected volatility was determined based on the historical volatility in the Company’s share prices in the Tel-Aviv Stock Exchange. The expected life of the options was determined according to Management’s estimate of the period the employees will hold the options, taking into consideration their position with the Company and the Company’s past experience regarding the turnover of employees. The risk‑free interest rate was determined based on the yield to maturity of shekel‑denominated Israeli Government debentures, with a remaining life equal or similar to the anticipated life of the option. The cost of the benefit embedded in the options and shares from the Equity Compensation Plan 2014 is recognized in the statement of income over the vesting period of each portion. Accordingly, in 2020, 2019, and 2018, the Company recorded expenses of $8 million, $12 million and $19 million, respectively. The movement in the options are as follows:
| Number of options (in millions)
| 2014 Plan
Balance as at January 1, 2019 | 18
Movement in 2019: |
Granted during the year | 19
Expired during the year | (3)
Forfeited during the year | (3)
Exercised during the year | (1)
Total options outstanding as at December 31, 2019 | 30
Movement in 2020: |
Expired during the year | (2)
Exercised during the year | (1)
Total options outstanding as at December 31, 2020 | 27
Note 19 – Equity (cont'd) C. Share-based payments (cont'd) 1. Non-marketable options (cont'd) The exercise prices for options outstanding at the beginning and end of each period are as follows:
| December 31, 2020 | December 31, 2019 | December 31, 2018
Granted 2014 US Dollar | - | 7.15 | 6.77
Granted 2015 US Dollar | - | - | 6.92
Granted 2016 US Dollar | 4.56 | 4.36 | 4.21
Granted 2017 US Dollar | 4.17 | 4.01 | 3.89
Granted 2018 US Dollar | 4.12 | 3.99 | 3.89
Granted 2019 US Dollar | 5.66 | 5.42 | -
The number of outstanding vested options at the end of each period and the weighted average exercise price for these options are as follows (*):
| December 31, 2020 | December 31, 2019 | December 31, 2018
Number of options exercisable (In Millions) | 11 | 12 | 11
Weighted average exercise price in Israeli Shekel | 13.89 | 15.19 | 18.53
Weighted average exercise price in US Dollar | 4.32 | 4.40 | 4.94
(*) The share price as of December 31, 2020, is NIS 16.36 and $5.09. The range of exercise prices for the options outstanding vested at the end of each period are as follows:
| December 31, 2020 | December 31, 2019 | December 31, 2018
Range of exercise price in Israeli Shekel | 13.15-18.32 | 13.55-24.71 | 14.26-25.93
Range of exercise price in US Dollar | 4.09-5.70 | 3.92-7.15 | 3.81-6.92
The average remaining contractual life for the outstanding vested options at the end of each period are as follows:
| December 31, 2020 | December 31, 2019 | December 31, 2018
Average remaining contractual life | 3.58 | 3.85 | 3.90
Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Restricted shares
Grant date | Employees entitled | Number of instruments (thousands) | Vesting conditions (*) | Instrument terms | Additional Information | Fair value at the grant date (Million)
August 6, 2014 | Officers and senior employees | 922 | 3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018 | An issuance for no consideration, under the 2014 Equity Compensation Plan. | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the date of the approval of the General Meeting where required). | 7.6
February 26, 2015 | ICL’s Directors (excluding ICL's CEO) | 99 | 3 tranches: (1) 50% will vest August 28, 2015 (2) 25% will vest February 26, 2017 (3) 25% will vest February 26, 2018 | 0.7
May 12, 2015 | Officers and senior employees | 1,194 | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | 8.8
June 29, 2015 | Former chairman of the BOD | 68
December 23, 2015 | ICL’s Directors (excluding ICL's CEO & Chairman of the BOD) | 121 | 3 equal tranches: (1) one third on December 23, 2016 (2) one third on December 23, 2017 (3) one third on December 23, 2018 | 0.5
June 30, 2016 | Officers and senior employees | 990 | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | 4.1
September 5, 2016 | Former chairman of BOD | 55
(*) Vesting of the Restricted Shares would be fully accelerated if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law. Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Restricted shares (cont’d)
Grant date | Employees entitled | Number of instruments (thousands) | Vesting conditions (*) | Instrument terms | Additional Information | Fair value at the grant date (Million)
January 3, 2017 | ICL’s Directors (excluding ICL's Chairman of the BOD) | 146 | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | An issuance for no consideration, under the 2014 Equity Compensation Plan. The value includes a reduction of 5% from the value of the equity compensation, pursuant to the decision of the directors in March 2016, to reduce their annual compensation for 2016 and 2017. | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the date of the approval of the General Meeting where required). | 0.6
February 14, 2017 | Former CEO | 38 | An issuance for no consideration, under the 2014 Equity Compensation Plan. | 0.2
June 20, 2017 | Officers and Senior employees | 2,211 | 10
August 2, 2017 | Former chairman of BOD | 53 | 0.3
January 10, 2018 | ICL’s Directors (excluding ICL's CEO & Chairman of the BOD) | 137 | 0.6
March 6, 2018 | Officers and senior employees | 1,726 | 8
May 14, 2018 | CEO | 121 | 0.6
August 20, 2018 | Former chairman of BOD | 47 | 0.2
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD) | 88 | Acceleration at January 2019. | 0.4
April 23, 2020 | ICL’s Directors (excluding directors who are officers or directors of Israel Corporation Ltd.) | 177 | 3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023 | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders). | 0.6
(*) Vesting of the Restricted Shares would be fully accelerated if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law. Note 19 – Equity (cont’d) C. Share-based payments (cont'd) Restricted shares (cont’d) In November 2019, March 2020 and April 2020, the Company’s HR & Compensation Committee, Board of Directors and shareholders, respectively, approved an equity grant for 2020 in the form of restricted shares, to the Company's directors (excluding directors whom are officers and directors of Israel Corporation Ltd.), in a value per grant of NIS 310,000 ($87,152). D. Dividends distributed to the Company's Shareholders
Board of Directors decision date to distribute the dividend | Actual date of distribution of the dividend | Gross amount of the dividend distributed (in millions of $) | Net amount of the distribution (net of the subsidiary’s share) (in millions of $) | Amount of the dividend per share (in $)
February 13, 2018 | March 14, 2018 | 70 | 69 | 0.05
May 10, 2018 | June 20, 2018 | 52 | 51 | 0.04
July 31, 2018 | September 4, 2018 | 56 | 56 | 0.04
October 31, 2018 | December 19, 2018 | 66 | 65 | 0.05
Total 2018 |  | 244 | 241 | 0.18
February 5, 2019 | March 13, 2019 | 62 | 61 | 0.05
May 7, 2019 | June 19, 2019 | 76 | 75 | 0.06
July 31, 2019 | September 24, 2019 | 74 | 73 | 0.06
November 6, 2019 | December 18, 2019 | 65 | 64 | 0.05
Total 2019 |  | 277 | 273 | 0.22
February 12, 2020 | March 18, 2020 | 23 | 23 | 0.02
May 11, 2020 | June 17, 2020 | 30 | 30 | 0.02
July 28, 2020 | September 16, 2020 | 36 | 36 | 0.03
November 11, 2020 | December 16, 2020 | 29 | 29 | 0.02
Total 2020 |  | 118 | 118 | 0.09
February 11, 2021 (after the reporting date)* | March 16, 2021 | 34 | 34 | 0.03
(*) The record date is March 3, 2021 and the payment date is March 16, 2021. Note 19 – Equity (cont’d) E. Cumulative translation adjustment The translation reserve includes all translation differences arising from translation of financial statements of foreign operations. F. Capital reserves The capital reserves include expenses for share‑based compensation to employees against a corresponding increase in equity (see section C. above) and change in investment at fair value through other comprehensive income (investment in 10% of the share capital of YYTH, see Note 21.E(3). G. Treasury shares During 2008 and 2009 22.4 million shares were acquired by the Group under a purchase plan, for a total consideration of approximately $258 million. Total shares held by the Group are about 24.5 million. 2) In determining the amount of retained earnings available for distribution as a dividend pursuant to the Israeli Companies Law, the amount of self‑acquisitions (that are presented separately in the “treasury shares” category in the equity section), must be deduct from the balance of the retained earnings. H. Retained earnings The retained earnings include actuarial gains (see Note 16.E) and dividends to the shareholders.

X
- References No definition available. + Details
Name: | icl_EquityExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_NotesToConsolidatedFinancialStatementsAbstract
Namespace Prefix: | icl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration